clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Chlamydial Pneumonia D061387 2 associated lipids
Sacroiliitis D058566 1 associated lipids
Plaque, Atherosclerotic D058226 7 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Upper Extremity Deep Vein Thrombosis D056824 1 associated lipids
Leprosy, Paucibacillary D056005 2 associated lipids
Extensively Drug-Resistant Tuberculosis D054908 1 associated lipids
Buruli Ulcer D054312 1 associated lipids
Immune Reconstitution Inflammatory Syndrome D054019 1 associated lipids
Renal Insufficiency D051437 8 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Epilepsy, Partial, Motor D020938 1 associated lipids
Central Nervous System Protozoal Infections D020808 3 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
alpha 1-Antitrypsin Deficiency D019896 3 associated lipids
Tooth, Nonvital D019553 2 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Carcinoma, Lewis Lung D018827 22 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Soft Tissue Infections D018461 2 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Cardiovascular Abnormalities D018376 2 associated lipids
Tuberculosis, Multidrug-Resistant D018088 6 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Community-Acquired Infections D017714 8 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Periodontal Attachment Loss D017622 7 associated lipids
Kleine-Levin Syndrome D017593 1 associated lipids
Cutaneous Fistula D017577 1 associated lipids
Pityriasis Rosea D017515 3 associated lipids
Dermatitis, Phototoxic D017484 4 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Liver Failure, Acute D017114 11 associated lipids
IgA Deficiency D017098 2 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Meningitis, Bacterial D016920 6 associated lipids
Angiomatosis, Bacillary D016917 2 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Empyema, Pleural D016724 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Helicobacter Infections D016481 21 associated lipids
Bacteremia D016470 9 associated lipids
Prosthesis-Related Infections D016459 7 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Eye Infections, Bacterial D015818 3 associated lipids
Eye Infections D015817 1 associated lipids
Eye Injuries, Penetrating D015807 2 associated lipids
Leprosy, Lepromatous D015440 2 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Discitis D015299 2 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Sexually Transmitted Diseases, Bacterial D015231 5 associated lipids
Wound Infection D014946 12 associated lipids
Whooping Cough D014917 6 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Urticaria D014581 13 associated lipids
Urination Disorders D014555 9 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Urethritis D014526 9 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Ureteral Diseases D014515 3 associated lipids
Typhoid Fever D014435 2 associated lipids
Tuberculosis, Spinal D014399 1 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
Tuberculosis, Ocular D014392 1 associated lipids
Tuberculosis, Avian D014379 2 associated lipids
Tuberculosis D014376 20 associated lipids
Tooth Discoloration D014075 7 associated lipids
Tenosynovitis D013717 3 associated lipids
Syphilis D013587 6 associated lipids
Synovitis D013585 15 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Stomach Ulcer D013276 75 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Stomach Diseases D013272 7 associated lipids
Sporotrichosis D013174 3 associated lipids
Splenic Diseases D013158 5 associated lipids
Skin Ulcer D012883 6 associated lipids
Skin Neoplasms D012878 12 associated lipids
Skin Diseases, Infectious D012874 7 associated lipids
Sinusitis D012852 9 associated lipids
Shock, Septic D012772 11 associated lipids
Serositis D012700 1 associated lipids
Scrub Typhus D012612 3 associated lipids
Rosacea D012393 13 associated lipids
Rodent Diseases D012376 4 associated lipids
Rickettsia Infections D012282 5 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Radiation Injuries D011832 14 associated lipids
Pyelonephritis D011704 5 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Psoriasis D011565 47 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Petersen AM et al. [Resistance of Helicobacter pylori to clarithomycin]. 1998 Ugeskr. Laeg. pmid:9627511
Archimandritis A et al. Clostridium difficile colitis associated with a 'triple' regimen, containing clarithromycin and metronidazole, to eradicate Helicobacter pylori. 1998 J. Intern. Med. pmid:9627163
Roussel G and Igual J Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. GETIM. Groupe d'Etude et de Traitement des Infections à Mycobactéries. 1998 Int. J. Tuberc. Lung Dis. pmid:9626603
Tsuneoka H et al. [Sensitivity of Helicobacter pylori to amoxicillin and clarythromycin with special reference to eradication therapy]. 1998 Kansenshogaku Zasshi pmid:9621560
Kruppa A et al. Immediate reaction to roxithromycin and prick test cross-sensitization to erythromycin and clarithromycin. 1998 Dermatology (Basel) pmid:9621142
Torresani C Clarithromycin: a new perspective in rosacea treatment. 1998 Int. J. Dermatol. pmid:9620480
Fischer BP et al. [Tsutsugamushi fever. Rare rickettsiosis after a stay in the Philippines]. 1998 Dtsch. Med. Wochenschr. pmid:9615696
Lilley LL and Guanci R A dangerous combination. 1998 Am J Nurs pmid:9612423
Ramon PM et al. [Uveitis, arthralgia and pseudo-jaundice in a HIV seronegative patient due to rifabutin]. 1998 Rev Mal Respir pmid:9608993
Gavura SR and Nusinowitz S Leukocytoclastic vasculitis associated with clarithromycin. 1998 Ann Pharmacother pmid:9606474
Moayyedi P et al. Relevance of antibiotic sensitivities in predicting failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori. 1998 J. Gastroenterol. pmid:9605943
Doherty TM and Sher A IL-12 promotes drug-induced clearance of Mycobacterium avium infection in mice. 1998 J. Immunol. pmid:9605144
Harris A Current regimens for treatment of Helicobacter pylori infection. 1998 Br. Med. Bull. pmid:9604443
Fujita K et al. [Neutrophil count and IL-8 level of nasal secretion of patients with chronic paranasal sinusitis and the effects of macrolide antibiotics]. 1998 Jpn J Antibiot pmid:9597505
Miyamoto N et al. [Test to set dosages for long-term administration of clarithromycin to treat chronic paranasal sinusitis]. 1998 Jpn J Antibiot pmid:9597498
Sasa K et al. [Antineoplastic therapeutic effect of clarithromycin in rats]. 1998 Jpn J Antibiot pmid:9597492
Yano S et al. [Significance of therapeutic efficacy of clarithromycin in a model for human lung cancer metastasis and a mouse tumor system]. 1998 Jpn J Antibiot pmid:9597491
Kokubo Y et al. [Effect of clarithromycin on experimental pulmonary metastasis]. 1998 Jpn J Antibiot pmid:9597488
Ueta K et al. [Evaluation of BRM (biological response modifier) action of clarithromycin (CAM)--effect on cytokine expression in a mouse lung cancer model]. 1998 Jpn J Antibiot pmid:9597487
Teramoto S et al. [Effect of clarithromycin administration on interferon-gamma and interleukin 12 mRNA expression in the tumor tissue of non-small-cell lung cancer]. 1998 Jpn J Antibiot pmid:9597486
Sakamoto M et al. [Efficacy of clarithromycin (CAM) in patients with inoperable non-small-cell lung cancer]. 1998 Jpn J Antibiot pmid:9597485
Ieshiro R et al. [Effect of clarithromycin in extending the life expectancy of patients with non-small-cell lung cancer--the second report]. 1998 Jpn J Antibiot pmid:9597484
Enomoto F et al. [Changes in adhesion molecule expressions in neutrophils caused by new macrolide administration]. 1998 Jpn J Antibiot pmid:9597482
Isono K et al. [Effects of macrolide antibiotics on neutrophil infiltration into the airway mucosa and ICAM-1 expression]. 1998 Jpn J Antibiot pmid:9597480
Salgado CG et al. [Study on the effects of macrolide antibiotics on the expression of B7-1, B7-2, and CD40 on epidermal Langerhans cells]. 1998 Jpn J Antibiot pmid:9597478
Iino Y et al. [Immunohistochemical study of the paranasal sinus mucosa of patients being treated with macrolide antibiotics--effects of antigen-presenting cells on the expression of a costimulator]. 1998 Jpn J Antibiot pmid:9597477
Konishi M et al. [Log-term administration of clarithromycin as a possible adjuvant therapy of HIV infections]. 1997 Jpn J Antibiot pmid:9597467
Yanagihara K et al. [Analysis of chronic respiratory tract infection by using an intubation model--evaluation based on fluctuations in cytokine content]. 1997 Jpn J Antibiot pmid:9597463
Mita Y et al. [Vitamin D3 induction of differentiation of HL-60 cells to monocyte- like cells and their aggregation--a dynamic culture method and clarithromycin]. 1997 Jpn J Antibiot pmid:9597462
Takeda H et al. [Macrolide antibiotic actions on bacteria and cultured airway cells]. 1997 Jpn J Antibiot pmid:9597448
Mikasa K et al. [Effect of clarithromycin on prolonging the life expectancy of patients with primary lung cancer]. 1997 Jpn J Antibiot pmid:9597439
Teramoto S et al. [Fluctuation in the cytokine m-RNA content in primary non-small cell lung cancer caused by clarithromycin (CAM) administration]. 1997 Jpn J Antibiot pmid:9597438
Sakamoto M et al. [Efficacy of clarithromycin on cancer cachexia in patients with primary non-small cell lung cancer]. 1997 Jpn J Antibiot pmid:9597437
Kokubo Y et al. [Effects of clarithromycin on experimental pulmonary metastasis]. 1997 Jpn J Antibiot pmid:9597436
Hamada K et al. [Evaluation of antineoplastic effect of CAM (clarithromycin) in a mouse model inoculated with lung cancer cells]. 1997 Jpn J Antibiot pmid:9597434
Sugihara J et al. [Efficacy of clarithromycin on chronic paranasal sinusitis--a comparison between children and adult]. 1997 Jpn J Antibiot pmid:9597431
Koster F Paradoxical local response to therapy for Mycobacterium avium complex infection in four patients with AIDS. 1998 Clin. Infect. Dis. pmid:9597260
van Aarem A et al. Recurrent therapy resistant mastoiditis by Mycobacterium cheilonae abscessus, a nontuberculous mycobacterium. 1998 Int. J. Pediatr. Otorhinolaryngol. pmid:9596371
Spangler SK et al. Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci. 1998 Antimicrob. Agents Chemother. pmid:9593160
Sörberg M et al. Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori. 1998 Antimicrob. Agents Chemother. pmid:9593154
Carr RA et al. Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration. 1998 Antimicrob. Agents Chemother. pmid:9593146
Goldstein EJ et al. Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans. 1998 Antimicrob. Agents Chemother. pmid:9593139
Liu W et al. [Clarithromycin combined short-term triple therapies for eradication of Helicobacter pylori infection]. 1996 Zhonghua Nei Ke Za Zhi pmid:9592304
Chen S et al. [Omeprazole, clarithromycin and amoxicillin therapy for Helicobacter pylori infection]. 1996 Zhonghua Nei Ke Za Zhi pmid:9592303
Sousa C et al. [Cholestatic hepatitis probably induced by clarithromycin]. 1997 Gastroenterol. Clin. Biol. pmid:9587506
Hasegawa M et al. [In vitro activities of faropenem against clarithromycin resistance Helicobacter pylori isolates]. 1998 Kansenshogaku Zasshi pmid:9585692
Sheu BS et al. One-week proton pump inhibitor-based triple therapy eradicates residual Helicobacter pylori after failed dual therapy. 1998 J. Formos. Med. Assoc. pmid:9585678
Tatsis G et al. Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections. 1998 J. Antimicrob. Chemother. pmid:9579716
Felmingham D et al. Antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens isolated in the UK during the 1995-1996 cold season. 1998 J. Antimicrob. Chemother. pmid:9578171
Schwartz H et al. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. 1998 Am. J. Gastroenterol. pmid:9576452